Dyne Therapeutics (DYN) News Today $10.30 -0.48 (-4.45%) Closing price 04:00 PM EasternExtended Trading$10.32 +0.01 (+0.15%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Dyne Therapeutics' (DYN) Buy Rating Reiterated at GuggenheimJune 19 at 3:40 AM | americanbankingnews.comParent Project Muscular Dystrophy Hosts 2025 Annual Conference in Las Vegas, NevadaJune 18 at 4:59 PM | finance.yahoo.comDyne at ‘attractive entry point’ following pullback, says ChardanJune 18 at 11:58 AM | finance.yahoo.comDyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating UpgradeJune 18 at 11:58 AM | seekingalpha.comDyne Therapeutics' (DYN) "Buy" Rating Reiterated at GuggenheimGuggenheim restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday.June 18 at 11:29 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNJune 18 at 10:25 AM | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Price Target Cut to $32.00 by Analysts at Robert W. BairdRobert W. Baird lowered their price target on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a report on Wednesday.June 18 at 9:57 AM | marketbeat.comDyne Therapeutics' (DYN) "Buy" Rating Reiterated at Chardan CapitalJune 18 at 2:35 AM | americanbankingnews.comDyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug TrialJune 18 at 2:26 AM | msn.comDyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYNJune 17 at 4:23 PM | tmcnet.comDyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYNJune 17 at 1:35 PM | businesswire.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's WhyDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Time to Sell?June 17 at 12:43 PM | marketbeat.comDyne Therapeutics stock falls after updated plan for accelerated approval in DM1June 17 at 11:22 AM | investing.comDyne falls amid delay in clinical program for muscle disorder therapyJune 17 at 11:22 AM | msn.comDyne Therapeutics Shares Slide After FDA Meeting Spurs Revised Accelerated Approval Plan for DM1 DrugJune 17 at 11:22 AM | msn.comWhy Is Dyne Therapeutics Stock Trading Lower On Tuesday?June 17 at 11:22 AM | benzinga.comChardan Capital Reiterates Buy Rating for Dyne Therapeutics (NASDAQ:DYN)Chardan Capital restated a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a report on Tuesday.June 17 at 10:01 AM | marketbeat.comDyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C MeetingJune 17 at 7:00 AM | globenewswire.comDyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ETJune 16, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Shares Down 3.3% - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Trading Down 3.3% - What's Next?June 16, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Position Boosted by SG Americas Securities LLCSG Americas Securities LLC grew its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 2,159.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 430,051 shares of the companJune 13, 2025 | marketbeat.comRaymond James Begins Coverage on Dyne Therapeutics (NASDAQ:DYN)June 13, 2025 | americanbankingnews.comRaymond James bullish on biotech firms on favorable valuationJune 12, 2025 | in.investing.comDyne Therapeutics (NASDAQ:DYN) Now Covered by Raymond JamesRaymond James began coverage on shares of Dyne Therapeutics in a research report on Wednesday. They issued an "outperform" rating and a $37.00 price target for the company.June 11, 2025 | marketbeat.comDyne Therapeutics officer sells shares worth $1,949June 8, 2025 | investing.comMillennium Management LLC Acquires 31,545 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Millennium Management LLC increased its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 526.5% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 37,536 shares of the company's stock after buying an additional 31,545 shares during the quarter.June 6, 2025 | marketbeat.comUS Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugsJune 5, 2025 | msn.comDyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research CongressJune 5, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Earns Outperform Rating from Analysts at OppenheimerOppenheimer assumed coverage on Dyne Therapeutics in a research report on Monday. They set an "outperform" rating and a $34.00 price target on the stock.June 2, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 56.1% in MayDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 23,200,000 shares, a growth of 56.1% from the April 30th total of 14,860,000 shares. Currently, 28.8% of the company's shares are short sold. Based on an average daily trading volume, of 2,440,000 shares, the days-to-cover ratio is presently 9.5 days.June 2, 2025 | marketbeat.comSquarepoint Ops LLC Has $1.22 Million Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Squarepoint Ops LLC cut its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 38.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,616 shares of the compaJune 1, 2025 | marketbeat.comBank of America Corp DE Decreases Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Bank of America Corp DE decreased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 58.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 122,641 shares of the company's stockJune 1, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Down 5.5% - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 5.5% - Here's WhyMay 31, 2025 | marketbeat.comEvercore ISI Initiates Coverage on Dyne Therapeutics (NASDAQ:DYN)Evercore ISI began coverage on shares of Dyne Therapeutics in a report on Thursday. They set an "outperform" rating and a $46.00 target price on the stock.May 30, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of "Buy" by BrokeragesShares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been given an average recommendation of "Buy" by the fourteen ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, eleven have given a buy recommendMay 30, 2025 | marketbeat.comVoloridge Investment Management LLC Makes New Investment in Dyne Therapeutics, Inc. (NASDAQ:DYN)Voloridge Investment Management LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 119,015 shares of the company's stock, valued aMay 29, 2025 | marketbeat.comDeutsche Bank AG Has $1.67 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Deutsche Bank AG raised its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 51.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 70,961 shares of the company's stock after bMay 26, 2025 | marketbeat.comWoodline Partners LP Sells 403,483 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Woodline Partners LP trimmed its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 41.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 573,957 shares of the company's stock after selling 403,483 shares duMay 24, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Shares Purchased by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 83.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 133,772 shares of the company'sMay 21, 2025 | marketbeat.com66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 66,998 shares of the company's stock, valued at approximately $1,578,000May 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases 822,201 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Point72 Asset Management L.P. grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 802.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 924,681 shares of the company's stock after acquiring an additional 822,201 shares duMay 20, 2025 | marketbeat.comMan Group plc Has $17.59 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Man Group plc raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 746,463 shares of the company's stock after purchasiMay 19, 2025 | marketbeat.comSphera Funds Management LTD. Grows Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Sphera Funds Management LTD. grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 318.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 236,262 shares of the company'May 18, 2025 | marketbeat.comRTW Investments LP Sells 1,600,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)RTW Investments LP reduced its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 23.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,218,641 shares of the company's stock after selling 1,600,000 shares during theMay 18, 2025 | marketbeat.comDimensional Fund Advisors LP Sells 66,569 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Dimensional Fund Advisors LP cut its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 40.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 99,578 shares of the company's stock aftMay 17, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Position Boosted by Comerica BankComerica Bank grew its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 20,133.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,409 shares of the company's stock after purchasing an additional 35,May 16, 2025 | marketbeat.comNorthern Trust Corp Increases Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Northern Trust Corp boosted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 7.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 777,013 shares of the company's stock after buying an additiMay 16, 2025 | marketbeat.comOrbimed Advisors LLC Purchases 518,680 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Orbimed Advisors LLC raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 73.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,227,080 shares of the company's stock after buying an additioMay 15, 2025 | marketbeat.comOctagon Capital Advisors LP Has $15.74 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)Octagon Capital Advisors LP lifted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 154.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 668,000 shares of the company's stocMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Invests $3.53 Million in Dyne Therapeutics, Inc. (NASDAQ:DYN)Integral Health Asset Management LLC purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 150,000 shares of the compaMay 14, 2025 | marketbeat.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.160.68▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼237▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Grifols News Today Telix Pharmaceuticals Limited American Depositary Shares News Today TG Therapeutics News Today Nuvalent News Today Lantheus News Today Axsome Therapeutics News Today ADMA Biologics News Today Zai Lab News Today Akero Therapeutics News Today Vaxcyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
